Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury

Abstract Traumatic brain injury (TBI) is set to become the leading cause of neurological disability across all age groups. Currently, no reliable biomarkers exist to help diagnose the severity of TBI to identify patients who are at risk of developing secondary injuries. Thus, the discovery of reliab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lisa J. Hill, Valentina Di Pietro, Jon Hazeldine, David Davies, Emma Toman, Ann Logan, Antonio Belli
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2e3ced1b215147288577674f59227d2d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e3ced1b215147288577674f59227d2d
record_format	dspace
spelling	oai:doaj.org-article:2e3ced1b215147288577674f59227d2d2021-12-02T12:32:29ZCystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury10.1038/s41598-017-04722-52045-2322https://doaj.org/article/2e3ced1b215147288577674f59227d2d2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04722-5https://doaj.org/toc/2045-2322Abstract Traumatic brain injury (TBI) is set to become the leading cause of neurological disability across all age groups. Currently, no reliable biomarkers exist to help diagnose the severity of TBI to identify patients who are at risk of developing secondary injuries. Thus, the discovery of reliable biomarkers for the management of TBI would improve clinical interventions. Inflammatory markers are particularly suited for biomarker discovery as TBI leads to very early alterations in inflammatory proteins. Using the Proseek Multiplex Inflammation assay, we measured in patients that had suffered mild TBI (n = 10) or severe TBI (n = 10) with extra-cranial injury or extracranial injury only (EC) (n = 10), 92 inflammation-associated proteins in serum obtained: <1 hr (within 1-hour), 4–12 hr and 48–72 hr post injury. Changes were compared to healthy volunteers (HV). Our results identified CST5, AXIN1 and TRAIL as novel early biomarkers of TBI. CST5 identified patients with severe TBI from all other cohorts and importantly was able to do so within the first hour of injury. AXIN1 and TRAIL were able to discriminate between TBI and HV at <1 hr. We conclude that CST5, AXIN1 and TRAIL are worthy of further study in the context of a pre-hospital or pitch-side test to detect brain injury.Lisa J. HillValentina Di PietroJon HazeldineDavid DaviesEmma TomanAnn LoganAntonio BelliNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lisa J. Hill Valentina Di Pietro Jon Hazeldine David Davies Emma Toman Ann Logan Antonio Belli Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
description	Abstract Traumatic brain injury (TBI) is set to become the leading cause of neurological disability across all age groups. Currently, no reliable biomarkers exist to help diagnose the severity of TBI to identify patients who are at risk of developing secondary injuries. Thus, the discovery of reliable biomarkers for the management of TBI would improve clinical interventions. Inflammatory markers are particularly suited for biomarker discovery as TBI leads to very early alterations in inflammatory proteins. Using the Proseek Multiplex Inflammation assay, we measured in patients that had suffered mild TBI (n = 10) or severe TBI (n = 10) with extra-cranial injury or extracranial injury only (EC) (n = 10), 92 inflammation-associated proteins in serum obtained: <1 hr (within 1-hour), 4–12 hr and 48–72 hr post injury. Changes were compared to healthy volunteers (HV). Our results identified CST5, AXIN1 and TRAIL as novel early biomarkers of TBI. CST5 identified patients with severe TBI from all other cohorts and importantly was able to do so within the first hour of injury. AXIN1 and TRAIL were able to discriminate between TBI and HV at <1 hr. We conclude that CST5, AXIN1 and TRAIL are worthy of further study in the context of a pre-hospital or pitch-side test to detect brain injury.
format	article
author	Lisa J. Hill Valentina Di Pietro Jon Hazeldine David Davies Emma Toman Ann Logan Antonio Belli
author_facet	Lisa J. Hill Valentina Di Pietro Jon Hazeldine David Davies Emma Toman Ann Logan Antonio Belli
author_sort	Lisa J. Hill
title	Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
title_short	Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
title_full	Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
title_fullStr	Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
title_full_unstemmed	Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury
title_sort	cystatin d (cst5): an ultra-early inflammatory biomarker of traumatic brain injury
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/2e3ced1b215147288577674f59227d2d
work_keys_str_mv	AT lisajhill cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT valentinadipietro cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT jonhazeldine cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT daviddavies cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT emmatoman cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT annlogan cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury AT antoniobelli cystatindcst5anultraearlyinflammatorybiomarkeroftraumaticbraininjury
_version_	1718394028740837376

Cystatin D (CST5): An ultra-early inflammatory biomarker of traumatic brain injury

Ejemplares similares